The North America AI In Cancer Diagnostics Market would witness market growth of 27.8% CAGR during the forecast period (2022-2028).
The complete and updated MRI-guided biopsies designed by the NCI scientists are now accessible in the clinic and hospitals which don’t require the need of cancer-specific professionals due to this AI tool. The new AI-featured algorithms have overpassed the abilities of professional radiologists by allowing the forecast of patient reports utilizing MRI. However, advanced AI methods can be employed to discover the gene mutations from tumor pathology images rather than utilizing standard genomic sequencing.
For example, scientists at New York University backed by the NCI utilized the deep learning technique to discover pathology images of lung tumors received from the Cancer Genome Atlas. Deep learning techniques can also be utilized to distinguish and detect Adenocarcinoma and squamous cell carcinoma which are the most prevalent lung cancer subtypes along with the identification of the altered genes from the images.
In collaboration with the Department of Energy (DOE), the Cancer Moonshot is assisting two crucial efforts to utilize its supercomputing expertise and capacity for cancer research and development. Moreover, Artificial intelligence is utilized to analyze and explain characteristics of the targeted molecules such as nucleic or protein acids that are crucial for the evolution of cancer also AI helps to predict new medication for targeted molecules and assets evaluating the efficacy of the medication.
Cancer is one of the foremost causes of mortality in the United States. The early-stage diagnosis of cancer is still a complicated procedure in most healthcare facilities. Due to the growing government actions and growing recession along with the enhancement in the healthcare industry. There were 863,830 female cases and 888,905 male cases of new invasive cancer recorded in the United States in 2019. The incidence rate for all cancers combined was 439 per 100,000 people in the general population.
The US market dominated the North America AI In Cancer Diagnostics Market by Country in 2021; thereby, achieving a market value of $146.7 million by 2028. The Canada market is experiencing a CAGR of 30.7% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 29.6% during (2022 - 2028).
Based on End-user, the market is segmented into Hospital, Surgical Centers & Medical Institutes and Others. Based on Component, the market is segmented into Software Solutions, Hardware and Services. Based on Cancer Type, the market is segmented into Breast Cancer, Lung Cancer, Brain Tumor, Skin Cancer & Cervical Cancer, Prostate & Colorectal Cancer and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Global AI In Cancer Diagnostics Market is Estimated to reach $509 Million by 2028, at a CAGR of 28.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Microsoft Corporation, Flatiron Health, Paige AI, Inc., PathAI, Inc., Therapixel, Tempus, Inc., SkinVision BV, Cancer Center Sp. z o.o., Medial EarlySign and Kheiron Medical Technologies Limited.
By End-user
By Component
By Cancer Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
